FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2565641320> ?p ?o ?g. }

• W2565641320 abstract "Abstract Abstract 1172 Poster Board I-194 Introduction: Acute and chronic graft versus host disease (aGVHD and cGVHD, respectively) cause significant morbidity and mortality following nonmyeloablative unrelated donor transplantation (NMUDT). The incidence of severe aGVHD (grades II-IV) following non-myeloablative transplant and standard GVHD prophylaxis (cyclosporine or tacrolimus plus mini-methotrexate or mycophenolate mofetil (i.e. two drug prophylaxis)) ranges between 40-70%. The incidence of cGVHD ranges between 50-70%. In order to decrease the incidence and severity of acute and chronic GVHD following NMUDT, consecutive patients were given triple prophylaxis therapy with tacrolimus (TAC), mycophenolate mofetil (MMF) and mini-methotrexate (MTX). In addition, patients were given anti-thymocyte globulin (ATG, thymoglobulin 10 mg/kg) as part of preparative therapy. Patients and Methods: Thirty-five consecutive patients meeting eligibility criteria for NMUDT were prospectively enrolled. The majority of patients had advanced disease; 9AML, 4 MDS, 2CML, 2MPD, 4 MM, 3CLL, 9 Lymphoma and 2 with aplastic anemia. The mean age was 53 years (26-68); 18 males and 17 females. Preparative therapy consisted of Fludarabine (F) 150mg/m2, Busulfan (Bu) 6.4mg/kg IV and ATG. All patients received stem cells from allele-matched unrelated donors; 9/10 (n= 13) or 10/10 (n= 22) at HLA A, B, C, DR and DQ. Thirteen patients received bone marrow and 22 patients received G-CSF mobilized blood stem cells. All patients received TAC (target 5-10 ug/L), MTX (5mg/m2 d1,3,6,11) and MMF (15mg/kg bid day 0 to 60) for GVHD prophylaxis. Infectious disease prophylaxis included; G-CSF, acyclovir, anti-bacterials, voriconazole, and CMV pre-emptive therapy. Results: The F/Bu/ATG non-myeloablative regimen was well tolerated. On average, patients experienced little or no mucositis (15% > grade 1), enteritis (3%> grade 1), skin toxicity (3% >grade 1) or liver toxicity (29% > grade 1). No VOD was seen. The median total bilirubin, alkaline phosphatase, ALT, and AST values post-transplant were 1.4 mg/dL, 153 U/L, 91 U/L and 77 U/L, respectively. The incidence of Grades II-IV and III-IV aGVHD were 26% and 6% respectively. No difference in aGVHD for 9/10 vs. 10/10 allele matched donors or those receiving stem cells vs. bone marrow was detected. The 100 day non-relapse mortality (NRM) was 11% (2 GVHD, 1 infection, 1 neurotoxicity). The incidence of cGVHD was 52% (80% extensive cGVHD). The majority of these patients required immunosuppression for >1 year. The 1 year NRM was 20% (2 GVHD, 2 infection, 2 neurotoxicity). Disease relapse was the most common cause of mortality; 37% overall and 17% within the first year of transplantation. The overall survival at 4 years is 41%. Conclusions: In this prospective study of 35 patients undergoing matched unrelated donor transplantation, the GVHD prophylaxis regimen of TAC/MTX/MMF is safe and effective. The low incidence of aGVHD (26%) compares favorably to published results. Only two patients experienced Grade IV aGVHD within 100 days of transplantation. Chronic GVHD and disease relapse remain problematic. Better strategies to prevent and treat cGVHD and disease relapse are needed. Disclosures: No relevant conflicts of interest to declare." @default.
• W2565641320 created "2017-01-06" @default.
• W2565641320 creator A5007298083 @default.
• W2565641320 creator A5012400900 @default.
• W2565641320 creator A5045294637 @default.
• W2565641320 creator A5060718239 @default.
• W2565641320 creator A5061334352 @default.
• W2565641320 creator A5077169512 @default.
• W2565641320 date "2009-11-20" @default.
• W2565641320 modified "2023-10-01" @default.
• W2565641320 title "Tacrolimus, Mini-Methotrexate and Mycophenolate Mofetil Is Safe and Effective as Acute Gvhd Prophylaxis for Non-Myeloablative Unrelated Donor Allogeneic Stem Cell Transplantation." @default.
• W2565641320 doi "https://doi.org/10.1182/blood.v114.22.1172.1172" @default.
• W2565641320 hasPublicationYear "2009" @default.
• W2565641320 type Work @default.
• W2565641320 sameAs 2565641320 @default.
• W2565641320 citedByCount "0" @default.
• W2565641320 crossrefType "journal-article" @default.
• W2565641320 hasAuthorship W2565641320A5007298083 @default.
• W2565641320 hasAuthorship W2565641320A5012400900 @default.
• W2565641320 hasAuthorship W2565641320A5045294637 @default.
• W2565641320 hasAuthorship W2565641320A5060718239 @default.
• W2565641320 hasAuthorship W2565641320A5061334352 @default.
• W2565641320 hasAuthorship W2565641320A5077169512 @default.
• W2565641320 hasConcept C120665830 @default.
• W2565641320 hasConcept C121332964 @default.
• W2565641320 hasConcept C126322002 @default.
• W2565641320 hasConcept C141071460 @default.
• W2565641320 hasConcept C2776694085 @default.
• W2565641320 hasConcept C2776755627 @default.
• W2565641320 hasConcept C2777408962 @default.
• W2565641320 hasConcept C2777630719 @default.
• W2565641320 hasConcept C2779263901 @default.
• W2565641320 hasConcept C2779972918 @default.
• W2565641320 hasConcept C2780007613 @default.
• W2565641320 hasConcept C2780611847 @default.
• W2565641320 hasConcept C2781059491 @default.
• W2565641320 hasConcept C2781440808 @default.
• W2565641320 hasConcept C2909675724 @default.
• W2565641320 hasConcept C2911091166 @default.
• W2565641320 hasConcept C61511704 @default.
• W2565641320 hasConcept C71924100 @default.
• W2565641320 hasConcept C90924648 @default.
• W2565641320 hasConceptScore W2565641320C120665830 @default.
• W2565641320 hasConceptScore W2565641320C121332964 @default.
• W2565641320 hasConceptScore W2565641320C126322002 @default.
• W2565641320 hasConceptScore W2565641320C141071460 @default.
• W2565641320 hasConceptScore W2565641320C2776694085 @default.
• W2565641320 hasConceptScore W2565641320C2776755627 @default.
• W2565641320 hasConceptScore W2565641320C2777408962 @default.
• W2565641320 hasConceptScore W2565641320C2777630719 @default.
• W2565641320 hasConceptScore W2565641320C2779263901 @default.
• W2565641320 hasConceptScore W2565641320C2779972918 @default.
• W2565641320 hasConceptScore W2565641320C2780007613 @default.
• W2565641320 hasConceptScore W2565641320C2780611847 @default.
• W2565641320 hasConceptScore W2565641320C2781059491 @default.
• W2565641320 hasConceptScore W2565641320C2781440808 @default.
• W2565641320 hasConceptScore W2565641320C2909675724 @default.
• W2565641320 hasConceptScore W2565641320C2911091166 @default.
• W2565641320 hasConceptScore W2565641320C61511704 @default.
• W2565641320 hasConceptScore W2565641320C71924100 @default.
• W2565641320 hasConceptScore W2565641320C90924648 @default.
• W2565641320 hasLocation W25656413201 @default.
• W2565641320 hasOpenAccess W2565641320 @default.
• W2565641320 hasPrimaryLocation W25656413201 @default.
• W2565641320 hasRelatedWork W1982767302 @default.
• W2565641320 hasRelatedWork W2050806087 @default.
• W2565641320 hasRelatedWork W2055468114 @default.
• W2565641320 hasRelatedWork W2062117877 @default.
• W2565641320 hasRelatedWork W2078042245 @default.
• W2565641320 hasRelatedWork W2298793602 @default.
• W2565641320 hasRelatedWork W2351451465 @default.
• W2565641320 hasRelatedWork W2369993144 @default.
• W2565641320 hasRelatedWork W2418478478 @default.
• W2565641320 hasRelatedWork W2556658425 @default.
• W2565641320 hasRelatedWork W2557361539 @default.
• W2565641320 hasRelatedWork W2561473476 @default.
• W2565641320 hasRelatedWork W2564934204 @default.
• W2565641320 hasRelatedWork W2578653763 @default.
• W2565641320 hasRelatedWork W2588687684 @default.
• W2565641320 hasRelatedWork W2701594823 @default.
• W2565641320 hasRelatedWork W2979912649 @default.
• W2565641320 hasRelatedWork W2980087679 @default.
• W2565641320 hasRelatedWork W3022007010 @default.
• W2565641320 hasRelatedWork W3138767028 @default.
• W2565641320 isParatext "false" @default.
• W2565641320 isRetracted "false" @default.
• W2565641320 magId "2565641320" @default.
• W2565641320 workType "article" @default.